A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)

NCT07247084 · tracked via the Priya Life Science UK tracker

Sponsor

Eli Lilly and Company

Phase

Phase 4

Started

2025-11-24

Last updated

2026-09-09

Condition(s) studied

Obesity

Investigational drug(s) / intervention(s)

TirzepatideStandard of Care

Tirzepatide: Administered SC

Standard of Care: Standard of care

Study summary

The purpose of this study is to evaluate tirzepatide within a real-world setting to assess body weight loss and incidence of type 2 diabetes in adults without diabetes who have obesity and at least one weight-related comorbid condition.

Eligible participants must be registered patients at a participating site. Participation in the study will last about 260 weeks.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Have a body mass index ≥30 and ≤34.9 kilogram per square meter (kg/m2) * Have an increased waist to height ratio (defined by \>0.5) * Have at least one weight related comorbid condition * Have had at least one attempt to lose weight with lifestyle intervention (diet and physical activity) Exclusion Criteria: * Have type 1 diabetes, type 2 diabetes, or any other types of diabetes * Have had a change in body weight of greater than 5 kilograms (11 pounds) within 90 days prior to screening

Primary outcome measure(s)

Percent Change from Baseline in Body Weight — Baseline, 24 months

Trial sites (30)

Facility	City	Region	Status
P91604 St John's Medical Centre	Altrincham	United Kingdom	Not Yet Recruiting
P89008 Ashton Medical Group	Ashton-under-Lyne	United Kingdom	Recruiting
Y02319 SSP Bolton General Practice	Bolton	United Kingdom	Not Yet Recruiting
P83012 Tower Family Healthcare	Bury	United Kingdom	Not Yet Recruiting
P91014 Washway Road Medical Centre	Cheshire	United Kingdom	Not Yet Recruiting
P88007 Cheadle Hulme Medical Group (was Cheadle Hulme Health Centre) (Bridge House)	Cheshire	United Kingdom	Not Yet Recruiting
Y02790 SSP Bolton Medical Centre	Great Lever	United Kingdom	Not Yet Recruiting
P89002 The Brooke Surgery	Hyde SK14	United Kingdom	Recruiting
P84035 Bodey Medical Centre	Manchester	United Kingdom	Recruiting
P84630 The Arch Medical Practice	Manchester	United Kingdom	Recruiting
P84678 Didsbury Medical Centre	Manchester	United Kingdom	Not Yet Recruiting
P84017 Ladybarn Group Practice	Manchester	United Kingdom	Not Yet Recruiting
P84068 Chorlton Family Practice	Manchester	United Kingdom	Not Yet Recruiting
P84012 Northenden Group Practice	Manchester	United Kingdom	Not Yet Recruiting
P86004 Peterloo Medical Centre	Manchester	United Kingdom	Recruiting
P83025 St Gabriels Medical Centre	Manchester	United Kingdom	Not Yet Recruiting
P87019 Silverdale Medical Practice	Manchester	United Kingdom	Recruiting
P91006 Urmston Group Practice	Manchester	United Kingdom	Not Yet Recruiting
P92620 SSP Ince Surgery (Lower Ince)	Manchester	United Kingdom	Not Yet Recruiting
P84034 Barlow Medical Centre	Manchester	United Kingdom	Not Yet Recruiting
P85010 Woodlands Medical Practice	Oldham	United Kingdom	Recruiting
P85011 CH Medical Practice	Oldham	United Kingdom	Recruiting
P86022 Stonefield Street Surgery	Rochdale	United Kingdom	Recruiting
P91021 Firsway Health Centre	Sale	United Kingdom	Not Yet Recruiting
P91013 Boundary House Medical Centre	Sale	United Kingdom	Not Yet Recruiting
P87027 Langworthy Medical Practice	Salford	United Kingdom	Recruiting
P88632 Stockport Medical Group	Stockport	United Kingdom	Not Yet Recruiting
P87016 The Sides Medical Centre	Swinton	United Kingdom	Recruiting
P87025 The Lakes Medical Practice	Swinton	United Kingdom	Recruiting
Y02322 SSP Leigh Family Practice	Wigen	United Kingdom	Not Yet Recruiting

On this site

📄 Mounjaro (tirzepatide) drug profile →

More Eli Lilly and Company trials in the UK

A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4066708 in Healthy Participants Recruiting

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) Recruiting

A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity Active, not recruiting

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) Active, not recruiting

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) Recruiting

Other trials for the same condition

A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity Active, not recruiting

Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes Recruiting

AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss Active, not recruiting

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) Recruiting

A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07247084 on ClinicalTrials.gov ↗ ← All trials in the UK